Pazopanib hydrochloride (GW 786034; GW786034B; SB 786034; Votrient) is an oral multi-targeted tyrosine kinase receptor inhibitor with anti-tumour activity. Pazopanib inhibits vascular endothelial growth factor receptor (VEGFR) 1, -2 and -3; platelet derived growth factor receptor (PDGFR); and c-kit; which may result in inhibition of angiogenesis in tumours in which these receptors are upregulated. It is intended to treat patients with advanced STS when prior chemotherapy has failed, is contraindicated, or refused by patients. Pazopanib is administered at 800mg once daily as monotherapy until disease progression or unacceptable toxicity.
Acute lymphoblastic leukaemia (ALL) is a type of cancer affecting white blood cells, which results in overproduction of faulty cells. These cells take over the bone marrow leading to anaemia, infection, bruising and bleeding. ALL is a rare condition, usually affecting more children than adults. Lymphoblastic lymphoma (LBL) is similar to ALL, they differ in where they often occur in the body (lymph nodes and thymus gland in LBL, and blood and bone marrow in ALL), and they are both treated in the same way.